Protalex Inc. (NASDAQ:PRTX) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

Shares of Protalex (NASDAQ:PRTX) remained flat at $0.90 during mid-day trading on Thursday. The company’s market cap is $25.89 million. The company’s 50-day moving average price is $0.88 and its 200 day moving average price is $0.81. Protalex has a 52-week low of $0.31 and a 52-week high of $3.00.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at

Protalex Company Profile

Protalex, Inc is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company’s lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system.

Receive News & Ratings for Protalex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex Inc. and related companies with's FREE daily email newsletter.